Julia L. McKechnie

Julia L. McKechnie, PhD has a diverse work experience. Julia L. is currently a Scientist in Immunology at Icosavax, Inc. since 2022. From 2020 to 2021, they were a Postdoctoral Research Fellow at Fred Hutch, where they used CRISPR/Cas9 to genetically engineer primary B cells to produce protective antibodies against viruses such as human immunodeficiency virus (HIV), respiratory syncytial virus (RSV), and SARS-CoV-2. From 2016 to 2020, they were a Graduate Student at Blish Laboratory, Stanford University School of Medicine, where they studied how the innate immune system responds to acute dengue virus (DENV) infection, with a particular focus on natural killer (NK) cells. From 2013 to 2016, they were an Undergraduate Research Assistant at Bertozzi Laboratory, University of California, Berkeley, where they synthesized and tested the in vitro efficacy of a trivalent probe which labels a glycoprotein of interest via bioorthogonal chemistry. Lastly, from 2012 to 2013, they were a Chemistry Department Summer Intern at Seagen Inc., where they investigated the in vitro effects of a small molecule fucosylation inhibitor to help assess whether it should move into clinical trials.

Julia L. McKechnie, PhD obtained their Bachelor of Science in Molecular Environmental Biology from the University of California, Berkeley between 2011 and 2015. Julia L. then went on to Stanford University School of Medicine where they earned their Doctor of Philosophy in Immunology between 2015 and 2020.